Candesartan cilexetil
Karbis and Canocord are different trade names for the same medicine.
The medicine is called Karbis. The active substance of the medicine is candesartan cilexetil. It belongs to a group of medicines called angiotensin II receptor antagonists. It causes relaxation and dilation of blood vessels. This helps to lower blood pressure. Karbis also makes it easier for the heart to pump blood to all parts of the body.
Karbis is used:
In case of doubts whether any of the above situations apply to the patient, they should consult a doctor or pharmacist before taking Karbis.
Before starting to take Karbis, the patient should discuss it with their doctor or pharmacist:
The doctor may monitor kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood at regular intervals.
See also the information under the heading "When not to take Karbis:".
The doctor may recommend more frequent checks and tests if any of the above points apply to the patient.
If the patient is going to have surgery, they should inform their doctor or dentist that they are taking Karbis. This is because Karbis, in combination with certain anesthetics, may cause a drop in blood pressure.
The use of Karbis has been studied in children. For further information, the patient should talk to their doctor. Karbis should not be given to children under 1 year of age due to the potential risk to kidney development.
The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or might take.
Karbis may affect the way other medicines work, and other medicines may affect the way Karbis works. If the patient is taking certain medicines, their doctor may periodically recommend blood tests.
In particular, the patient should inform their doctor if they are taking the following medicines:
The doctor may need to change the dose and/or take other precautions:
Karbis can be taken with or without food.
The patient should consult their doctor if they plan to consume alcohol while taking Karbis. Karbis may cause dizziness or fainting.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
Pregnancy
The patient should inform their doctor about suspected (or planned) pregnancy. The doctor will usually recommend stopping Karbis before planned pregnancy or as soon as pregnancy is confirmed and recommend taking a different medicine instead of Karbis. Karbis is not recommended during early pregnancy and should not be taken after 3 months of pregnancy, as it may seriously harm the baby (see section "Pregnancy and breastfeeding").
Breastfeeding
The patient should inform their doctor about breastfeeding or intending to breastfeed. Karbis is not recommended during breastfeeding, especially in the case of breastfeeding a newborn or premature baby. The doctor may recommend a different medicine.
While taking Karbis, some patients may feel tired and dizzy. If such symptoms occur, the patient should not drive, use tools, or operate machines.
If the patient has been told by their doctor that they have an intolerance to some sugars, they should contact their doctor before taking this medicine.
This medicine should always be taken exactly as the doctor or pharmacist has told the patient. If the patient is unsure, they should ask their doctor or pharmacist. It is important to take Karbis every day.
Karbis is available in the following strengths: 8 mg, 16 mg, 32 mg.
Karbis can be taken with or without food. The tablet should be swallowed with water. The tablets should be taken every day at about the same time. This will help the patient remember to take their dose. The tablet can be divided into equal doses.
The recommended dose of candesartan is 8 mg once a day. The doctor may increase the dose to 16 mg once a day, and then to 32 mg once a day, depending on the patient's response to treatment.
The doctor may recommend a lower initial dose for certain patients, e.g., patients with liver or kidney problems, patients who have lost a lot of fluid, e.g., due to vomiting, diarrhea, or the use of diuretics.
In some black patients, the response to treatment may be weaker if Karbis is used as monotherapy. In that case, higher doses may be necessary.
Children from 6 to 18 years of age:
The recommended initial dose is 4 mg once a day.
Patients with a body weight of less than 50 kg: in some patients with inadequate blood pressure control, the doctor may decide to increase the dose of Karbis to a maximum of 8 mg once a day.
Patients with a body weight of 50 kg or more: in some patients with inadequate blood pressure control, the doctor may decide to increase the dose of Karbis to 8 mg once a day and then to 16 mg once a day.
The recommended initial dose of candesartan is 4 mg once a day. The doctor may increase the dose by doubling it, at intervals of at least 2 weeks, to 32 mg once a day. Karbis can be taken with other medicines used to treat heart failure, and the doctor will decide which therapy is most suitable for the patient.
If the patient has taken a higher dose of Karbis than recommended, they should contact their doctor or pharmacist immediately.
The patient should not take a double dose to make up for a forgotten dose. They should take the next dose at the usual time.
Stopping treatment may lead to a rise in blood pressure again. The patient should not stop taking Karbis unless their doctor tells them to.
If the patient has any further questions about the use of this medicine, they should ask their doctor or pharmacist.
Like all medicines, Karbis can cause side effects, although not everybody gets them.
It is important that the patient knows about the possibility of these effects.
Karbis may cause a decrease in the number of white blood cells. This may lead to a reduced ability to fight infections, and the patient may experience tiredness, infection, or fever. If such symptoms occur, the patient should contact their doctor. The doctor may periodically recommend blood tests to check if Karbis is causing any blood disorders (agranulocytosis).
Other possible side effects include:
Side effects in children treated for high blood pressure appear to be similar to those seen in adults, but they occur more frequently. Very common side effects in children include pharyngitis, common cold, fever, and rapid heart rate, but these side effects were not seen in adults.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, the patient can help provide more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
There are no special storage instructions.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
The 8 mg tablets are pink, round, slightly convex with beveled edges and a score line on one side, with a diameter of 7 mm.
The tablet can be divided into equal doses.
Pack sizes: 14, 28, 30, 56, 60, or 84 tablets in blisters, in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Str. 5, 27472 Cuxhaven, Germany
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in the Czech Republic, the country of export:58/565/11-C
Parallel import authorization number:374/18
Date of leaflet approval: 01.02.2022
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.